Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study
Journal of Investigative Dermatology Feb 10, 2022
Findings of this small pilot study demonstrate high effectiveness of topical ruxolitinib in treating cutaneous lichen planus (LP). In transcriptomic analysis, LP was corroborated as an interferon-driven disease and downregulation of interferon-stimulated genes was shown to be correlated with disease response.
Ruxolitinib is a Janus kinase 1/2 inhibitor that blocks signal transduction of interferon-gamma, an important cytokine implicated in the pathogenesis of cutaneous LP.
This prospective phase II study included 12 patients with cutaneous LP who were instructed to apply topical ruxolitinib twice daily for 8 weeks.
Total lesion count reduced by a median of 50 lesions (interquartile range 25, 723; p<0.001).
At week 4, there was a decrease in modified Composite Assessment of Index Lesion Severity scores by a mean difference of 7.6 (standard deviation 8.8, p=0.016) between index treated and control lesions.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries